[Systemic sclerosis: paths into the future].
Guillevin
Loïc
L
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077300:Bosentan; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D005544:Forecasting; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D044062:Prostaglandins I / Q000008:administration & dosage / Q000627:therapeutic use; D011687:Purines; D011788:Quality of Life; D012106:Research; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000534:rehabilitation / Q000628:therapy; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013450:Sulfones; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D044062:Prostaglandins I; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D000077300:Bosentan